Last updated on July 2020

Mild Alzheimer’s Disease Study in patients with Glucose Intolerance (T2DM)

Brief description of study

We are enrolling participants in a new mild Alzheimer’s clinical trial. This trial will evaluate the safety and effectiveness of the study medication, azeligaron in the treatment of mild Alzheimer’s disease in patients who also have glucose intolerance or Type 2 Diabetes: those with HGbA1c of 6.5% to 9.5%).

Study participation will last about eleven months. Following an approximate 60 day screening period, qualified participants will be randomly assigned to the study medication, azeligaron, or a placebo (an inactive substance). During the treatment period, the participants will visit the research center 2 times over a 6 month period. All participants will come back 3 months after the final study visit for a follow-up visit.


Clinical Study Identifier: TX228542

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.